JP2019527194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527194A5 JP2019527194A5 JP2018563050A JP2018563050A JP2019527194A5 JP 2019527194 A5 JP2019527194 A5 JP 2019527194A5 JP 2018563050 A JP2018563050 A JP 2018563050A JP 2018563050 A JP2018563050 A JP 2018563050A JP 2019527194 A5 JP2019527194 A5 JP 2019527194A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims description 82
- 239000012634 fragment Substances 0.000 claims description 81
- 239000000427 antigen Substances 0.000 claims description 77
- 102000036639 antigens Human genes 0.000 claims description 77
- 108091007433 antigens Proteins 0.000 claims description 77
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 18
- 208000018737 Parkinson disease Diseases 0.000 claims description 10
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 9
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 208000032859 Synucleinopathies Diseases 0.000 claims description 7
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 6
- 201000002832 Lewy body dementia Diseases 0.000 claims description 6
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 101000787265 Homo sapiens Beta-synuclein Proteins 0.000 claims description 3
- 101000787273 Homo sapiens Gamma-synuclein Proteins 0.000 claims description 3
- 101000834885 Macaca fascicularis Alpha-synuclein Proteins 0.000 claims description 3
- 101000834882 Rattus norvegicus Alpha-synuclein Proteins 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000005540 biological transmission Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 101150110503 END3 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000019355 Synuclein Human genes 0.000 description 1
- 108050006783 Synuclein Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022082099A JP2022110117A (ja) | 2016-06-02 | 2022-05-19 | α－シヌクレインに対する抗体およびその使用 |
| JP2024103562A JP7823118B2 (ja) | 2016-06-02 | 2024-06-27 | α－シヌクレインに対する抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344746P | 2016-06-02 | 2016-06-02 | |
| US62/344,746 | 2016-06-02 | ||
| PCT/EP2017/063406 WO2017207739A1 (en) | 2016-06-02 | 2017-06-01 | Antibodies to alpha-synuclein and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022082099A Division JP2022110117A (ja) | 2016-06-02 | 2022-05-19 | α－シヌクレインに対する抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527194A JP2019527194A (ja) | 2019-09-26 |
| JP2019527194A5 true JP2019527194A5 (https=) | 2020-07-09 |
| JP7078552B2 JP7078552B2 (ja) | 2022-05-31 |
Family
ID=59021492
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563050A Active JP7078552B2 (ja) | 2016-06-02 | 2017-06-01 | α－シヌクレインに対する抗体およびその使用 |
| JP2022082099A Pending JP2022110117A (ja) | 2016-06-02 | 2022-05-19 | α－シヌクレインに対する抗体およびその使用 |
| JP2024103562A Active JP7823118B2 (ja) | 2016-06-02 | 2024-06-27 | α－シヌクレインに対する抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022082099A Pending JP2022110117A (ja) | 2016-06-02 | 2022-05-19 | α－シヌクレインに対する抗体およびその使用 |
| JP2024103562A Active JP7823118B2 (ja) | 2016-06-02 | 2024-06-27 | α－シヌクレインに対する抗体およびその使用 |
Country Status (37)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| AR110074A1 (es) | 2016-11-15 | 2019-02-20 | H Lundbeck As | Agentes, usos y métodos para el tratamiento de la sinucleinopatía |
| CN110072888B (zh) | 2016-12-16 | 2023-07-18 | H.隆德贝克有限公司 | 药剂、用途和方法 |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| CN110506057B (zh) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | Alpha突触核蛋白抗体及其应用 |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| WO2020079113A1 (en) * | 2018-10-19 | 2020-04-23 | Janssen Vaccines & Prevention B.V. | Anti-synuclein antibodies |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| KR20210154179A (ko) | 2019-04-18 | 2021-12-20 | 에이씨 이뮨 에스.에이. | 치료 및 진단용 신규한 분자 |
| CN110172098B (zh) * | 2019-05-27 | 2023-03-10 | 长春工业大学 | 抗α-突触核蛋白的单克隆抗体及其应用 |
| US20230074436A1 (en) | 2019-09-20 | 2023-03-09 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| KR102239512B1 (ko) * | 2020-09-10 | 2021-04-12 | 서울대학교산학협력단 | 다중기능성 마이크로캡슐 조성물 및 그 제조방법 |
| EP4229082A1 (en) | 2020-10-16 | 2023-08-23 | AC Immune SA | Antibodies binding to alpha-synuclein for therapy and diagnosis |
| CN112920274A (zh) * | 2021-03-17 | 2021-06-08 | 江苏贝格尔生物医药有限公司 | 一种检测alpha-synuclein蛋白的鼠单克隆抗体及其应用 |
| CN113912716B (zh) * | 2021-12-15 | 2022-03-01 | 北京凯祥弘康生物科技有限公司 | 针对α-突触核蛋白抗原的抗体及其应用 |
| KR20250148576A (ko) | 2022-12-29 | 2025-10-14 | 아스트라제네카 아베 | 알파-시누클레인병증을 치료하기 위한 조성물 및 방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0108923B8 (pt) | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| US7943129B2 (en) | 2000-05-26 | 2011-05-17 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| SI1633189T1 (sl) | 2003-05-19 | 2017-12-29 | Prothena Biosciences Limited | Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
| US20090047300A1 (en) | 2005-09-27 | 2009-02-19 | Abedelnasser Abulrob | Blood-brain barrier epitopes and uses thereof |
| PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| JP4934074B2 (ja) | 2007-03-07 | 2012-05-16 | 株式会社アルファ | スイッチ固定構造 |
| PT2282758T (pt) | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| AU2009328505B2 (en) | 2008-12-19 | 2014-11-27 | Panima Pharmaceuticals Ag | Human anti-alpha-synuclein autoantibodies |
| JP4654348B1 (ja) | 2010-02-23 | 2011-03-16 | 多摩川精機株式会社 | 検出装置用巻線の正弦波巻線方法 |
| CA2789963C (en) | 2010-02-26 | 2019-09-03 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| HUE041391T2 (hu) | 2011-06-23 | 2019-05-28 | Biogen Int Neuroscience Gmbh | Anti-alfa-szinukleinkötõ molekulák |
| US8609820B2 (en) | 2011-10-28 | 2013-12-17 | Neotope Biosciences Limited | Humanized antibodies that recognize alpha-synuclein |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| CA2924268C (en) * | 2013-11-21 | 2021-05-18 | F. Hoffmann-La Roche Ag | Anti-alpha-synuclein antibodies and methods of use |
| DK3218406T4 (da) | 2014-11-10 | 2024-12-09 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
-
2017
- 2017-06-01 CN CN201780045951.2A patent/CN109475616B/zh active Active
- 2017-06-01 UA UAA201811679A patent/UA124733C2/uk unknown
- 2017-06-01 AU AU2017272804A patent/AU2017272804B2/en active Active
- 2017-06-01 SM SM20220008T patent/SMT202200008T1/it unknown
- 2017-06-01 MA MA45125A patent/MA45125B1/fr unknown
- 2017-06-01 SI SI201731025T patent/SI3463435T1/sl unknown
- 2017-06-01 TW TW106118078A patent/TWI765890B/zh active
- 2017-06-01 WO PCT/EP2017/063406 patent/WO2017207739A1/en not_active Ceased
- 2017-06-01 MD MDE20190406T patent/MD3463435T2/ro unknown
- 2017-06-01 DK DK17728525.1T patent/DK3463435T3/da active
- 2017-06-01 ES ES17728525T patent/ES2903402T3/es active Active
- 2017-06-01 HR HRP20211935TT patent/HRP20211935T1/hr unknown
- 2017-06-01 PL PL17728525T patent/PL3463435T3/pl unknown
- 2017-06-01 SG SG11201810420YA patent/SG11201810420YA/en unknown
- 2017-06-01 LT LTEPPCT/EP2017/063406T patent/LT3463435T/lt unknown
- 2017-06-01 EA EA201892548A patent/EA038358B1/ru unknown
- 2017-06-01 CN CN202211223767.1A patent/CN116120445A/zh active Pending
- 2017-06-01 EA EA202191380A patent/EA202191380A1/ru unknown
- 2017-06-01 HU HUE17728525A patent/HUE057214T2/hu unknown
- 2017-06-01 PE PE2018003155A patent/PE20190440A1/es unknown
- 2017-06-01 BR BR112018074978-8A patent/BR112018074978A2/pt active Search and Examination
- 2017-06-01 RS RS20211502A patent/RS62682B1/sr unknown
- 2017-06-01 AR ARP170101504A patent/AR108663A1/es unknown
- 2017-06-01 TW TW111117603A patent/TW202309093A/zh unknown
- 2017-06-01 JP JP2018563050A patent/JP7078552B2/ja active Active
- 2017-06-01 EP EP17728525.1A patent/EP3463435B1/en active Active
- 2017-06-01 KR KR1020187037675A patent/KR102499438B1/ko active Active
- 2017-06-01 GE GEAP202114964A patent/GEAP202114964A/en unknown
- 2017-06-01 EP EP21202106.7A patent/EP4000632A1/en active Pending
- 2017-06-01 MX MX2018014456A patent/MX393740B/es unknown
- 2017-06-01 PE PE2023002924A patent/PE20250392A1/es unknown
- 2017-06-01 PT PT177285251T patent/PT3463435T/pt unknown
- 2017-06-01 US US15/611,416 patent/US10160800B2/en active Active
- 2017-06-01 GE GEAP201714964A patent/GEP20217253B/en unknown
- 2017-06-01 CA CA3025987A patent/CA3025987A1/en active Pending
- 2017-06-01 MY MYPI2018002168A patent/MY188183A/en unknown
-
2018
- 2018-10-25 US US16/170,468 patent/US10889639B2/en active Active
- 2018-11-22 IL IL263243A patent/IL263243A/en unknown
- 2018-11-29 PH PH12018502538A patent/PH12018502538A1/en unknown
- 2018-11-30 CL CL2018003438A patent/CL2018003438A1/es unknown
- 2018-12-19 ZA ZA2018/08582A patent/ZA201808582B/en unknown
- 2018-12-21 CO CONC2018/0014010A patent/CO2018014010A2/es unknown
- 2018-12-28 EC ECSENADI201896095A patent/ECSP18096095A/es unknown
-
2020
- 2020-12-03 US US17/111,159 patent/US11560424B2/en active Active
-
2022
- 2022-01-05 CY CY20221100010T patent/CY1124896T1/el unknown
- 2022-05-19 JP JP2022082099A patent/JP2022110117A/ja active Pending
-
2023
- 2023-01-20 US US18/099,671 patent/US20230331830A1/en active Pending
-
2024
- 2024-01-31 AU AU2024200601A patent/AU2024200601A1/en active Pending
- 2024-06-27 JP JP2024103562A patent/JP7823118B2/ja active Active
-
2025
- 2025-01-16 US US19/025,554 patent/US20250263477A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527194A5 (https=) | ||
| AU2022252753B2 (en) | ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF | |
| KR101629365B1 (ko) | 항원 결합성 단백질 | |
| JP2022110117A (ja) | α－シヌクレインに対する抗体およびその使用 | |
| CN112424223B (zh) | 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途 | |
| EP3261720B1 (en) | Antibodies to tau and uses thereof | |
| JP7045724B2 (ja) | 配列類似性を持つ抗ファミリー１９、メンバーａ５抗体及びその用途 | |
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| KR102263812B1 (ko) | a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도 | |
| JP7766392B2 (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| JP2017536354A5 (https=) | ||
| TW201018482A (en) | Novel treatment | |
| CN108517010A (zh) | 识别α-突触核蛋白的人源化抗体 | |
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP6808611B2 (ja) | Ｆｃγ受容体ＩＩＢおよびＦｃε受容体に対する新規の抗体 | |
| JP2018529635A5 (https=) | ||
| JP2021518761A (ja) | 配列類似性１９、メンバーａ５抗体を有する抗ファミリー及びその使用方法 | |
| CN116847887A (zh) | 治疗自身免疫性疾病和癌症的方法和组合物 | |
| JP2021511387A5 (https=) | ||
| CA3242070A1 (en) | Antibodies recognizing sortilin | |
| US20260028396A1 (en) | Anti-myostatin antibodies and methods | |
| CA3236199A1 (en) | Anti-amyloid beta antibodies and methods of using the same | |
| KR20250019593A (ko) | 항체 및 이를 포함하는 면역질환 치료용 약학적 조성물 | |
| WO2026064762A1 (en) | Anti-myostatin antibodies and methods | |
| CN120882746A (zh) | 结合至nkg2a和pd-l1的药剂及其用途 |